qlc7401
Small moleculeexperimental
Clinical trial activity
2 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Feb 28, 2025 (NCT06750341)
Timeline
Indications
Studied for
Mechanism of action
- Subtilisin/kexin type 9INHIBITOR
PCSK9 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07074236 | Phase 1 | Jul 31, 2025 | Qilu Pharmaceutical Co., Ltd. |
| NCT06750341 | Phase 2 | Feb 28, 2025 | Qilu Pharmaceutical Co., Ltd. |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Qilu Pharmaceutical Co., Ltd. | For profit | 2 | 2 | 2 | 2025 |
1 organizations
Page 1 / 1